PhaseBio Pharmaceuticals
-
Malvern’s PhaseBio Enjoys ‘a Truly Momentous Occasion’ with Licensing Agreement Worth Up to $245 Million
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia Business…
-
CEO of Malvern-Based PhaseBio Building Company for the Long Haul
Last year, Malvern-based PhaseBio Pharmaceuticals went public and raised $46 million through an initial public stock offering, writes John George for the Philadelphia Business Journal.…
-
Malvern’s PhaseBio Awarded $2.8 Million Grant from National Institutes of Health
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has been awarded a $2.8 million grant. The Fast Track Small…
-
Malvern’s PhaseBio Raises $15 Million, Shifts Toward New Drug for Orphan Diseases
Malvern’s PhaseBio Pharmaceuticals has switched its focus from diabetes treatments to orphan diseases by closing a nearly $15 million round of financing to help advance…
-
PhaseBio Closes Refinancing With AstraZeneca To Further Drug Trials
PhaseBio Pharmaceuticals, Inc. of Malvern has closed a $40 million Series C financing round led by AstraZeneca. The clinical-stage biopharmaceutical firm is focused on biopolymer-based…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
